Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash & Equivalents (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Cash & Equivalents for 9 consecutive years, with $128.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 32.02% to $128.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $128.4 million through Dec 2025, up 32.02% year-over-year, with the annual reading at $128.4 million for FY2025, 32.02% up from the prior year.
  • Cash & Equivalents hit $128.4 million in Q4 2025 for Protagonist Therapeutics, up from $113.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $355.6 million in Q2 2024 to a low of $83.0 million in Q1 2021.
  • Historically, Cash & Equivalents has averaged $155.2 million across 5 years, with a median of $129.8 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 95.77% in 2023 and later tumbled 52.61% in 2025.
  • Year by year, Cash & Equivalents stood at $123.7 million in 2021, then grew by 1.68% to $125.7 million in 2022, then surged by 48.5% to $186.7 million in 2023, then plummeted by 47.92% to $97.2 million in 2024, then skyrocketed by 32.02% to $128.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for PTGX at $128.4 million in Q4 2025, $113.7 million in Q3 2025, and $168.5 million in Q2 2025.